Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.
Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder. One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause. Off-label, paroxetine may be used for the treatment of premature ejaculation or irritable bowel syndrome (IBS).
Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil
Academic Medical Centre Amsterdam, Amsterdam, Netherlands
Reinier de Graaf Groep, Delft, Netherlands
University Medical Centre Groningen, Groningen, Netherlands
Shanghai Mental Health Center, Shanghai, China
Columbia University/New York State Psychiatric Institute, New York, New York, United States
Emory University, Atlanta, Georgia, United States
Beijing Anding Hospital, Beijing, Beijing, China
Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.